Clinical trial registry record

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 16, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01397409
Last registry update
April 16, 2019
Status
Completed
Phase
Phase 2
Sponsor
Allergan
Enrollment
271
Countries
United States, Australia, Austria, France, Germany, Israel, Italy, Switzerland
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
271
Population
ALL · 50 Years
Duration
2011-09-01 to 2014-04-30
Intervention
AGN-150998; ranibizumab; Sham Injection
Comparator
Stage 2: ranibizumab 0.5 mg; Stage 3: ranibizumab 0.5 mg
Outcomes measured
Highest Tolerated Dose (HTD) of AGN-150998 — 24 Weeks; Stage 1: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye — Baseline, Week 4; Stage 2: Time Between Baseline Treatment and Recurrence of Active Disease — Baseline, Week 16; Stage 3: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, Week 16; Stage 2: Time Between Second Treatment and Recurrence of Active Disease — 32 Weeks; Stage 2: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye — Baseline, Week 4; Stage 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, Week 4; Stage 3: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye — Baseline, Week 4; Stage 3: Change From Baseline in BCVA in the Study Eye — Baseline, Week 4
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON